VIRACTA THERAPEUTICS, INC.

(VIRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Viracta Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

01/04/2022 | 09:01am EDT

SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present at the H.C. Wainwright BIOCONNECT Virtual Conference.

The pre-recorded webcast will be available for on-demand viewing beginning Monday, January 10, 2022, at 7:00 a.m. ET on the Investors section of the Viracta website under "Events and Webcasts" at https://viracta.investorroom.com/events-and-webcasts. The webcast will be archived for 90 days.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy, Nana-Val, in a pivotal Phase 2 clinical trial for EBV-positive (EBV+) lymphoma and a Phase 1b/2 trial in patients with EBVnasopharyngeal carcinoma and other EBV+ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers.

For additional information please visit www.viracta.com.

Investor Relations Contact:
Ashleigh Barreto
Head of Investor Relations & Corporate Communication
Viracta Therapeutics, Inc.
abarreto@viracta.com

Viracta Therapeutics, Inc. Logo (PRNewsfoto/Viracta Therapeutics, Inc.)

 

Cision
View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-the-hc-wainwright-bioconnect-virtual-conference-301453062.html

SOURCE Viracta Therapeutics, Inc.


© PRNewswire 2022
All news about VIRACTA THERAPEUTICS, INC.
05/13Viracta Therapeutics Announces New Employment Inducement Grant
PR
05/11Viracta Therapeutics to Present at Upcoming May Investor Conferences
PR
05/10SUNESIS : Q1 Earnings Snapshot
AQ
05/10VIRACTA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition..
AQ
05/10Viracta Therapeutics Reports First Quarter 2022 Financial Results and Recent Updates
PR
04/27VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/27TRANSCRIPT : Viracta Therapeutics, Inc. - Special Call
CI
04/20Viracta Therapeutics to Host Key Opinion Leader Webinar on Nana-val for the Treatment o..
PR
04/15VIRACTA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
04/15Viracta Therapeutics, Inc. Announces That Gur Roshwalb Will Not Stand for Re-Election A..
CI
More news
Analyst Recommendations on VIRACTA THERAPEUTICS, INC.
More recommendations